The success of an allogeneic hematopoietic SCT (HSCT) is dependent on a multitude of factors, including the procurement of an optimal graft source. 1 Further, the quality of this graft depends on a variety of donor and/or host characteristics. Most importantly, HLA compatibility between the recipient and donor is considered the dominant characteristic in this field, 2 where it remains paramount in ensuring the potential success of the allogeneic HSCT. However, there are other important donor characteristics. These non-HLA characteristics may be broadly considered to be either traditional characteristics, such as ABO compatibility or novel, such as cytokine or KIR polymorphisms. Unsurprisingly, traditional characteristics have been reviewed extensively while novel characteristics are less studied. With better HLA matching techniques, 3 these non-HLA donor characteristics would be further scrutinized, with a view that optimizing them would lead to improved transplant outcomes. Consequently, we sought to understand the relative priorities that the physicians of the Canadian Blood and Marrow Transplant Group (CBMTG) place on such non-HLA donor characteristics using conjoint analysis (CA), a pair-wise choice-based survey method.
CA is a survey method of data collection and analysis originally developed in mathematical psychology and marketing, and has close theoretical links to multi-attribute utility theory. 4 The basic premise of this technique is that any service or good can be described by characteristics, and the extent to which the individual values a good or service depends on the levels of these characteristics. It allows the estimation of the marginal rates of substitution, relative importance of each characteristic and the trade-offs between the characteristics.
In preparation for our CA, we performed a systematic review of the literature using standardized 5 methodology (fourth week of 2006), where we identified 12 broad donor characteristics, excluding HLA compatibility. Subsequently, we surveyed CBMTG members (n ¼ 117) in summer 2007 using the Survey Monkey 6 interface where respondents (response rate of 50%) were asked to consider the list of donor characteristics identified by the systematic review and to add any further donor characteristics that they deemed important. Subsequently, they were asked to name their 'top' four donor characteristics (in no particular order) that they consider in their practice. These four donor characteristics were: (1) donor relatedness, (2) age, (3) gender and (4) CMV compatibility.
Each of the four identified donor characteristic can be considered to have two levels (for example, related vs unrelated donor). With 4 attributes with 2 levels each, there could be 2 4 that is,16 possible combinations. Because of the high number of possible combinations, an orthogonal fractional factorial design was implemented using the SPEED 2.1 software. 7 The software sampled the different combinations of characteristics and their levels, while ensuring that all combinations are represented. This produced pairs of characteristics; the characteristic pairs were then used to produce scenarios. In this case, the number of scenarios presented in the CA was reduced to 10 (5 paired comparisons), thereby diminishing the risk of fatigue or disinterest.
Using a hypothetical case of a 30-year CMV sero-negative male with AML in CR1 wherein an allogeneic HSCT was deemed the most appropriate management, five scenarios were developed wherein they differ only by the potential donors offered (an example is shown in Figure 1 ). Specifically, the donor characteristics were varied from scenario to scenario. One of the choices was a dominant scenario (scenario 3) to ensure respondents understood the CA concept and that the eventual responses can be considered consistent and valid.
The CA with paired comparisons were presented to CBMTG members (n ¼ 114) via an Internet-based survey, again using the Survey Monkey interface (autumn 2007). Our overall response rate was 39%, with 61% of the respondents identifying themselves as physicians. All respondents chose the dominant scenario in scenario 3, validating comprehension of the CA, and the results of the remaining scenarios are displayed in Table 1 . Subsequently, a multilogit model was chosen given the repeated measurements of data from the same individuals for our CA, where the analyses were performed using SAS v9.1 (Cary, NC, USA).
Our results demonstrate that the CBMTG members, and physicians in particular, strongly indicate preference for donors related to recipients (hazards ratio (HR) 2.97) over the donor's age, gender and CMV compatibility (Table 1) . Further, our analysis could suggest that respondents prefer older female donors, which is counterintuitive. The orthogonal fractional factorial design did not provide scenarios where either relatedness or CMV status was compared with a combination of other desirable characteristics. Thus, in the four scenarios where respondents were asked to trade between desirable characteristics, respondents were also asked to trade either donor relatedness or CMV negative status with either age or gender. It is clear that the majority of respondents strongly favored CMV status and relatedness over age and gender, thus reducing the trading between characteristics. This limits further analysis and may contribute to non-intuitive results. For example, in scenario 1, the unwillingness to trade donor relatedness for a male donor can falsely be interpreted as a preference for a female donor.
Other notable limitations to the results of the CA are worth mentioning. First, the full response rate for CA was 39%. It is possible that the preferences for respondents may be different from that of non-respondents. Second, the scenarios were hypothetical and 'force' respondents to consider a specific transplant scenario. Furthermore, it is possible that only one stem cell donor exists, limiting the option of the transplant team. Third, it could be argued that the order of clinical scenarios may influence the choice of the respondent. However, the dominant scenario (scenario 3) was chosen by all the respondents, implying that the conjoint task was understood. Furthermore, the order of scenarios within the CA task does not influence results.
HSCT is associated with improved 5-year overall survival rates for recipients (33, 29 and 25%, with donors aged 18-30, 31-45 and 445 years, respectively, (P ¼ 0.0002). 8 Further, the rates of acute and chronic GVHD were lower with younger donors. Indeed, several groups have suggested that the HSCT outcomes are similar with an appropriate younger unrelated donor instead of an older related donor. [9] [10] [11] This is particularly salient given the increasing age of HSCT 12 and decreasing family size. 13 Similar registry studies have evaluated the influence of CMV compatibility, suggesting that CMV disparate HSCT may fare worse. 14, 15 In contrast, an individual patient data meta analysis suggests that ABO compatibility does not significantly influence HSCT outcomes. Despite these and other studies, it remains difficult to fully evaluate the relative importance of these non-HLA donor characteristics. Importantly, many of the clinical outcomes reviewed in the individual studies may not adjust fully for possible confounding factors. Even when adjustments were made, the adjustments varied across studies. Clinical outcomes after allogeneic HSCT are varied and dependent on a variety of factors. Donor characteristics have a role; however, the degree of importance is interdependent on other recipient, transplant and disease factors. Thus, clinical improvements in one area will highlight the relative importance of another. The paucity of definitive data likely influenced the CBMTG members' beliefs. Indeed, the majority of the CBMTG members were unwilling to 'trade-off' donor relatedness and CMV negativity, limiting the results of the CA. Nevertheless, it is clear that in 2007, the CBMTG members, including the physicians, strongly value relatedness (HR 2.97) over donor age, gender and CMV compatibility. Future surveys may demonstrate a change in donor preferences; particularly when CBMTG members are presented with a choice between a younger unrelated donor with an older related donor.
